It's nice to see a detailed 4C. Despite the diminishing share price since mid-Feb there has been some great achievements in that period and the report details them well.
ALA is funded until preliminary data from Phase 1 trails and part of the focus this year is the further development of it's solid tumor products.
No red flags in this for mine.
It's nice to see a detailed 4C. Despite the diminishing share...
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.3¢ |
Change
-0.003(2.17%) |
Mkt cap ! $126.0M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.0¢ | $67.34K | 582.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 565311 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 50462 | 5 |
View Market Depth
| Last trade - 15.12pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.5¢ |
Change
-0.003 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.8¢ | 12.0¢ | 11.5¢ | 189773 | ||
| Last updated 15.12pm 21/05/2024 ? | |||||
| ALA (ASX) Chart |